“In the latest tussle over access to medicines, patient advocates in India are attempting to prevent Gilead Sciences from obtaining a patent for its forthcoming hepatitis C treatment, which is called sofosbuvir, over concerns that pricing will make the drug out of reach for many people.”
Partner with us now to build a more just and equitable medicine system for all. Notice: JavaScript is required for this content.